Sales

5,920mn

In CHF

Sales Growth

6.8

In%

Sales Million CHF
Historical Progression - sales (bar chart)

1Reported pro-forma full-year 2017 financial results (restated for IFRS 15) include Capsugel full-year 2017 financial result

CORE RONOA

28.5

In %

ROIC

9.1

In %

CORE RONOA In %
Historical Progression - CORE RONOA (bar chart)
CORE EBITDA1

1,620mn

In CHF

CORE EBITDA Margin

27.4

In %

1IFRS 16 accounting adjustment on leases had a positive CORE EBITDA impact of CHF 33 mn in 2019 (60 bps positive CORE EBITDA margin impact), offset by costs related to the divestment of the Water Care business and carve-out of Specialty Ingredients (50 bps negative CORE EBITDA margin impact). IFRS Results – Continuing Business: EBITDA – CHF 1,525 mn; EBITDA Margin – 25.8%

CORE EBITDA Million CHF
CORE EBITDA Margin In %
Historical Progression - CORE EBITDA and CORE EBITDA Margin (bar chart)

1Reported pro-forma full-year 2017 financial results (restated for IFRS 15) include Capsugel full-year 2017 financial result

CORE EBIT2

1,245mn

In CHF

CORE EBIT Margin2

21.0

In %

2IFRS 16 accounting adjustment on leases had a positive CORE EBIT impact of CHF 2 million in 2019 (3 bps positive CORE EBIT margin impact), offset by costs related to the divestment of the Water Care business and carve-out of Specialty Ingredients (50 bps negative CORE EBIT margin impact). IFRS Results – Continuing Business: EBIT – CHF 972 mn; EBIT Margin – 16.4%

CORE EBIT Million CHF
CORE EBIT Margin In %
Historical Progression - CORE EBIT and CORE EBIT Margin (bar chart)

1Reported pro-forma full-year 2017 financial results (restated for IFRS 15) include Capsugel full-year 2017 financial result

Capital Expenditures (CAPEX) Million CHF
CAPEX/Sales In %
Historical Progression - Capital Expenditures (bar chart)
Net Debt/CORE EBITDA Ratio
Historical Progression - Net Debt / CORE EBITDA (bar chart)

>30

Countries Around the World

>55

Manufacturing Sites

>1,040

Small and Large Molecules1

>5,600

Trademark Filings

>575

Active Patent Families

>800

Brands Globally

15,468

Employees End of 2019

1Small Molecules include active pharmaceutical ingredients (API), highly potent API (HPAPI) and dosage form and delivery systems. Large Molecules include mammalian and microbial, cell & gene therapy products, applied protein services and drug product services

Ten-Year Overview of Major Highlights

Million CHF

 

2010

2011

2012

2013

2014

2015

2016

2017

20181

2019

Sales

 

2,680

2,692

3,925

3,584

3,640

3,803

4,132

4,548

5,542

5,920

CORE EBITDA

 

n.a.

n.a.

663

711

743

793

918

1,196

1,511

1,620

Margin in %

 

n.a.

n.a.

16.9

19.8

20.4

20.9

22.2

26.5

27.3

27.4

EBITDA

 

643

537

645

647

737

780

848

1,084

1,429

1,525

Margin in %

 

24.0

19.9

16.4

18.1

20.2

20.5

20.5

23.8

25.8

25.8

CORE EBIT

 

387

326

398

436

475

524

651

904

1,165

1,245

Margin in %

 

14.4

12.1

10.1

12.2

13.0

13.8

15.8

20.1

21.0

21.0

Result from operating activities (EBIT)

 

374

261

340

253

423

428

486

673

842

972

Margin in %

 

14.0

9.7

8.7

7.1

11.6

11.3

11.8

14.8

15.2

16.4

CORE RONOA in %

 

n.a.

n.a.

8.8

12.3

14.3

16.4

21.5

30.0

31.4

28.5

RONOA3 in %

 

10.8

6.9

7.5

5.9

10.3

10.8

12.7

9.8

12.1

12.9

ROIC2,3 in %

 

n.a.

n.a.

n.a.

n.a.

n.a.

n.a.

n.a.

8.4

8.0

9.1

CORE EPS (diluted)

CHF

5.81

4.34

4.54

4.97

6.76

6.76

8.38

10.78

11.98

13.59

EPS (diluted)

CHF

5.53

2.97

3.35

1.67

4.54

5.26

5.69

9.70

8.77

10.22

Operational free cash flow (bef. acquisitions)

 

362

127

510

519

476

693

638

658

884

495

Net debt

 

1,108

2,647

2,301

2,103

2,011

1,660

1,584

3,762

3,534

2,961

Net debt/CORE EBITDA

 

n.a.

n.a.

3.47

2.96

2.70

2.09

1.73

2.70

2.28

1.83

Number of employees (Full-Time Equivalent)

 

8,280

11,001

10,789

9,935

9,809

9,829

10,130

14,618

15,375

15,468

Net Operating Assets (NOA)3

 

2,970

4,205

3,990

3,916

4,094

3,739

3,739

6,852

6,795

7,423

1

Lonza continuing operations, excluding Water Care business classified as discontinued operations, except for “Net debt”, “Net debt/CORE EBITDA” and “Headcount”

2

Introduced in 2018, comparable data for 2017 was provided

3

Refer to Alternative Performance Measures section of the Financial Report for more details of the calculation methodology

(XLS:) Download

(PDF:) Download section PDF Financials Download Center